<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117451</article-id><article-id pub-id-type="publisher-id">ACM-43983</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_54406130.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  伴纤维蛋白原异常的IgA-λ型多发性骨髓瘤1例并文献复习
  IgA-λ Multiple Myeloma with Abnormal Fibrigon: A Case Report and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>金玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>玉娇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>颜</surname><given-names>学申</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>广伦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>牛</surname><given-names>文验</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>中光</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3113</fpage><lpage>3116</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  多发性骨髓瘤是浆细胞恶性克隆性疾病，临床表现多样，少数患者存在出血倾向，以鼻出血和牙龈出血多见，本例患者为中老年女性，首发鼻出血及皮肤出血，测纤维蛋白原明显减低，骨穿见成熟红细胞呈明显缗钱状排列，原幼浆细胞占ANC 54.5%，免疫球蛋白(血)：IgA 87.70 g/L，λ轻链23.70 g/L。诊断：多发性骨髓瘤(IgA-λ型)。
   Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells with various clinical manifestations. A few patients have bleeding tendency, especially nosebleeds and gingival bleeding. This patient is a middle-aged and old woman, with epistaxis and skin bleeding as the first manifestations. The fibrinogen is obviously reduced, and the mature red blood cells are obviously arranged in a money-like way after bone penetration. The protoplasmic cells account for 54.5% of ANC, and immunoglobulin (blood): IgA 87.70 g/L, λ 23.70 g/L. Diagnosis: Multiple myeloma (IgA-λ type).
 
</p></abstract><kwd-group><kwd>多发性骨髓瘤，IgA-λ型，α链，异常纤维蛋白原血症，出血, Multiple Myeloma</kwd><kwd> IgA-λ Type</kwd><kwd> Chain α</kwd><kwd> Dysfibrinogenemia</kwd><kwd> Bleeding</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>多发性骨髓瘤是浆细胞恶性克隆性疾病，临床表现多样，少数患者存在出血倾向，以鼻出血和牙龈出血多见，本例患者为中老年女性，首发鼻出血及皮肤出血，测纤维蛋白原明显减低，骨穿见成熟红细胞呈明显缗钱状排列，原幼浆细胞占ANC 54.5%，免疫球蛋白(血)：IgA 87.70 g/L，λ轻链23.70 g/L。诊断：多发性骨髓瘤(IgA-λ型)。</p></sec><sec id="s2"><title>关键词</title><p>多发性骨髓瘤，IgA-λ型，α链，异常纤维蛋白原血症，出血</p></sec><sec id="s3"><title>IgA-λ Multiple Myeloma with Abnormal Fibrigon: A Case Report and Literature Review<sup> </sup></title><p>Jinyu Li<sup>*</sup>, Juan Du, Yujiao Sun, Xueshen Yan, Guanglun Li, Wenyan Niu, Zhongguang Cui<sup>#</sup></p><p>Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/32-1572390x4_hanspub.png?20210721082758175" /></p><p>Received: Jun. 12<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/32-1572390x5_hanspub.png?20210721082758175" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells with various clinical manifestations. A few patients have bleeding tendency, especially nosebleeds and gingival bleeding. This patient is a middle-aged and old woman, with epistaxis and skin bleeding as the first manifestations. The fibrinogen is obviously reduced, and the mature red blood cells are obviously arranged in a money-like way after bone penetration. The protoplasmic cells account for 54.5% of ANC, and immunoglobulin (blood): IgA 87.70 g/L, λ 23.70 g/L. Diagnosis: Multiple myeloma (IgA-λ type).</p><p>Keywords:Multiple Myeloma, IgA-λ Type, Chain α, Dysfibrinogenemia, Bleeding</p><disp-formula id="hanspub.43983-formula22"><graphic xlink:href="//html.hanspub.org/file/32-1572390x7_hanspub.png?20210721082758175"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/32-1572390x8_hanspub.png?20210721082758175" /> <img src="//html.hanspub.org/file/32-1572390x9_hanspub.png?20210721082758175" /></p></sec><sec id="s5"><title>1. 引言</title><p>多发性骨髓瘤是血液系统恶性肿瘤，其临床表现多样，首发表现以贫血、骨痛、肾功能不全及高钙血症多见，少数患者存在出血倾向，以鼻出血和牙龈出血多见，本例患者以鼻出血及皮肤出血起病，且有“杀鼠药”接触史，测纤维蛋白原明显减低，PT及APTT均明显延长，容易误诊为出血性疾病。</p></sec><sec id="s6"><title>2. 病例资料</title><p>患者，女，54岁，因“间断鼻衄1周”于2021-01-04至我院门诊就诊。患者就诊前1周间断鼻衄，偶有口唇血泡，下肢瘀斑。既往体健，否认肝肾疾病，否认服用抗凝药物，可疑“鼠药”接触史，否认出血性疾病家族史。查体：神志清，贫血貌，口唇可见血痂，浅表淋巴结无肿大，胸骨无压痛，心肺腹查体无异常，双下肢散在瘀斑及色素沉着。查血凝常规：PT 20.8 sec (10.5~14.5)，PT百分活动度44% (70~150)，APTT 54.8 sec (28~43)，TT 38.2 sec (12~25)，FIB &lt; 0.2 g/L (1.8~3.8)，D-二聚体450 ng/ml；与检验科沟通后复查FIB &lt; 1.76 g/L；血常规：WBC 8.25 * 10<sup>9</sup>/L；Hb 68.00 g/L，MCV 98.3 fl；PLT 142.00 * 10<sup>9</sup>/L。考虑凝血功能障碍。予维生素K肌注，并嘱定期复查血凝常规；完善凝血因子及贫血相关检测。2021-01-11复诊，凝血因子示：VIII 85.7%；IX 84.2%；XI 72.7%。贫血相关检测示铁蛋白、维生素B12及叶酸均在正常范围。患者应用维生素k1后鼻衄好转，逐渐出现下腰背部疼痛，伴头晕、乏力。复查血凝常规：PT 14.8 sec，APTT 32.5 sec；TT 40.1 sec，FIB 2.05 g/L，D-二聚体450 ng/ml；血常规：WBC 10.16 * 10<sup>9</sup>/L；Hb 68.00 g/L，MCV 98.3 fl；PLT 141.00 * 10<sup>9</sup>/L；患者中度正细胞正色素性贫血，合并骨痛，骨髓瘤不能排除，完善全身CT示：双侧部分肋骨、部分胸腰椎体、骶骨、髂骨诸骨骨质密度不均，局部斑片状低密度，边界不清。骨髓片：有核细胞增生明显活跃，G = 21.00%、E = 10.00%、G/E = 2.1:1；粒系增生活跃，比例减低，形态大致正常；红系增生活跃，比例减低，形态大致正常，成熟红细胞呈明显缗钱状排列；淋巴细胞、单核细胞未见特殊；全片共见巨核14个，血小板小簇可见，数量正常；浆细胞数量明显增多，占ANC 63.5%，其中原幼浆细胞占ANC 54.5%，可见多核浆细胞。血片：白细胞略多，偶见幼稚粒细胞；成熟红细胞呈明显缗钱状排列，计数100个白细胞可见1个有核红细胞；血小板散在可见，数量正常；偶见浆细胞。免疫组化：CD38多灶(+)，CD138多灶(+)，CD56多灶(+)，κ (−)，λ多灶(+)，CD20少(+)，E-CAD小丛(+)，MPO散在(+)。FISH示IGH/FGFR3阳性(120/200)，p53基因(17p13.1)缺失阳性(48/200)，RB1 (13q14)基因缺失阳性(145/200)，IGH/MAF及IGH/CCNH1阴性，尿蛋白示免疫球蛋白GAM、λ轻链泳道发现疑似沉淀条带。肾功：尿酸376.5 umol/L，肌酐98.2 umol/L；免疫球蛋白(血)：IgA 87.70 g/L；κ轻链0.82 g/L，λ轻链23.70 g/L，Kappa/Lambda 0.03；M带成分63.50%；β2微球蛋白3.98 mg/L；24小时尿蛋白排泄量0.15 g/24小时；白蛋白19.5 g/L。全脊椎MR：C2椎体、C4、6附件多发结节状高压脂信号，边界清楚；胸椎椎体、附件、肋骨信号减低，压制信号增高，T2、T10~12椎体、部分棘突、肋骨见多发结节状更高压脂信号，边界清楚。腰椎诸椎体压脂信号增高，部分椎体、附件内见更高压脂信号，以L3椎体为著，L3、5椎体变扁，压缩性骨折。诊断：多发性骨髓瘤(IgA-λ型，Durie-Salmon分期III期，R-ISS分期II期)。排除化疗禁忌，患者于2021-02-02开始第1疗程VTD方案化疗，具体为：沙利度胺100 mg d1-21，硼替佐米2 mg d1-4-8-11，地塞米松20.25 mg d1-21，02-06复查PT 15.9 sec，APTT 29.3 sec，TT 29.2 sec，FIB 1.51 g/L；02-09 PT 11.9 sec，APTT 31.7 sec，TT 19.9 sec (12~25)，FIB 2.48 g/L；IgA 55.2 g/L，免疫球蛋白λ轻链5.21 g/L。患者现VTD方案治疗过程中，纤维蛋白原恢复正常水平，且血红蛋白逐步上升。</p></sec><sec id="s7"><title>3. 讨论</title><p>多发性骨髓瘤是浆细胞恶性克隆性疾病，临床表现多样，涉及多个系统 [<xref ref-type="bibr" rid="hanspub.43983-ref1">1</xref>]，少数患者存在出血倾向，以鼻出血和牙龈出血多见，具体原因有：① 血小板数量减少；M蛋白包裹血小板影响其功能；② 凝血障碍：M蛋白可与纤维蛋白单体结合，影响纤维蛋白多聚化；M蛋白直接影响VIII因子活性；③ M蛋白及淀粉样变性损伤毛细血管。纤维蛋白原作为凝血系统的最主要成分，是止血过程中重要的凝血因子，有报道IgGκ型MM产生的M蛋白可与纤维蛋白原的β链相互作用，改变纤维蛋白聚合和形态，从而导致出血症状 [<xref ref-type="bibr" rid="hanspub.43983-ref2">2</xref>]。本例患者外周血中血小板及VIII因子正常，接触“杀鼠药”，纤维蛋白原水平低下，APTT、PT及TT均明显延长，其首诊时提供的临床资料均指向出血性疾病，极易误诊、漏诊。此例MM患者体内过多的单克隆免疫球蛋白导致纤维蛋白原结构异常，从而使得其功能异常并难以用常规手段检测，表现为低纤维蛋白原血症。纤维蛋白原依赖于维生素K，是一种由肝脏薄壁组织细胞合成的急性期糖蛋白，分子量为340 kDa，结构为α2β2γ2，是内、外源性凝血共同途径的组成部分，是血浆中含量最高的凝血因子，在血浆中正常浓度为2.0~4.0 g/L，其功能及数量异常均可导致广泛的凝血障碍 [<xref ref-type="bibr" rid="hanspub.43983-ref3">3</xref>]。纤维蛋白原异常可分为两大类：I型缺陷，即纤维蛋白原数量的缺陷，指无纤维蛋白原血症或者低纤维蛋白原血症，血浆纤维蛋白原水平降低或者缺失；II型缺陷，即纤维蛋白原质量的缺陷，指异常纤维蛋白原血症或者低异常纤维蛋白原血症，血浆纤维蛋白原抗原水平正常或者降低，而活性却不成比例的显著降低。大多数异常纤维蛋白原血症是有基因缺陷导致，少部分为外界因素导致的获得性 [<xref ref-type="bibr" rid="hanspub.43983-ref4">4</xref>]。本病例中患者的纤维蛋白原初诊时虽无法测出，但复测后处于低水平，应归为II型缺陷，且成年发病，考虑获得性异常纤维蛋白原血症。获得性纤维蛋白原血症通常继发于肝脏疾病，如肝硬化、肝癌 [<xref ref-type="bibr" rid="hanspub.43983-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.43983-ref6">6</xref>]，骨髓瘤 [<xref ref-type="bibr" rid="hanspub.43983-ref7">7</xref>]，副肿瘤综合征及免疫性疾病，此外，可能和某些药物及骨髓移植有关 [<xref ref-type="bibr" rid="hanspub.43983-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43983-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.43983-ref9">9</xref>]。个别MM病例存在高纤维蛋白原血症 [<xref ref-type="bibr" rid="hanspub.43983-ref10">10</xref>]，国内未有报道IgA-λ型MM表现为低纤维蛋白原血症。国外存在1例IgA-λ型意义未明的单克隆免疫球蛋白血症患者表现为低纤维蛋白原血症，研究者通过ELISA法观察到IgA的α轻链可与纤维蛋白原结合，并推测：M蛋白与纤维蛋白原非特异性结合或两者以抗原抗体形式结合，在电镜先证实了IgA可改变纤维蛋白构成的网格结构 [<xref ref-type="bibr" rid="hanspub.43983-ref7">7</xref>]。</p><p>存在相关器官受损的MM诱导治疗多以蛋白酶体抑制剂联合免疫调节剂及地塞米松的3药联合方案为主 [<xref ref-type="bibr" rid="hanspub.43983-ref11">11</xref>]。本例患者确诊后应用VTD方案，复查M蛋白显著降低，血凝基本恢复正常，贫血改善。</p><p>综上所述，MM合并出血在临床上少见，尤其合并异常纤维蛋白原血症更甚，极易误导临床医师做出诊断，此时，应充分询问病史，患者首发鼻出血，伴皮肤出血，无内脏及重要脏器出血表现，合并非营养性贫血，且逐渐出现腰背痛的症状，均指向血液系统恶性肿瘤，而纤维蛋白溶解亢进及早期出血是急性早幼粒细胞白血病(APL)的显著临床特征 [<xref ref-type="bibr" rid="hanspub.43983-ref12">12</xref>]，故本病例应与急性早幼粒细胞白血病相鉴别，骨髓穿刺对明确诊断至关重要。诊断后应用一线方案VTD即可获得良好的治疗效果。</p></sec><sec id="s8"><title>声明</title><p>该病例报道获得患者的知情同意。</p></sec><sec id="s9"><title>文章引用</title><p>李金玉,杜 娟,孙玉娇,颜学申,李广伦,牛文验,崔中光. 伴纤维蛋白原异常的IgA-λ型多发性骨髓瘤1例并文献复习IgA-λ Multiple Myeloma with Abnormal Fibrigon: A Case Report and Literature Review[J]. 临床医学进展, 2021, 11(07): 3113-3116. https://doi.org/10.12677/ACM.2021.117451</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43983-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.V., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncology, 15, e538-e548.  
&lt;br&gt;https://doi.org/10.1016/S1470-2045(14)70442-5</mixed-citation></ref><ref id="hanspub.43983-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kotlín, R., Sobotková, A., Riedel, T., et al. (2008) Acquired Dysfibrinogenemia Secondary to Multiple Myeloma. Acta Haematologica, 120, 75-81. &lt;br&gt;https://doi.org/10.1159/000160182</mixed-citation></ref><ref id="hanspub.43983-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mosesson, M.W. (2010) Fibrinogen and Fibrin Structure and Functions. Journal of Thrombosis &amp; Haemostasis, 3, 1894-1904. &lt;br&gt;https://doi.org/10.1111/j.1538-7836.2005.01365.x</mixed-citation></ref><ref id="hanspub.43983-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Casini, A., Neerman-Arbez, M., Ariëns, R.A., et al. (2015) Dysfibrinogenemia: From Molecular Anomalies to Clinical Manifestations and Management. Journal of Thrombosis and Haemostasis, 13, 909-919.  
&lt;br&gt;https://doi.org/10.1111/jth.12916</mixed-citation></ref><ref id="hanspub.43983-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Regañón, E., Vila, V., Aznar, J., Garrido, G., Estellés, A. and Berenguer, J. (1987) Study of the Formation of Fibrin Clot in Cirrhotic Patients: An Approach to Study of Acquired Dysfibrinogenemia. Thrombosis Research, 46, 705-714.  
&lt;br&gt;https://doi.org/10.1016/0049-3848(87)90272-6</mixed-citation></ref><ref id="hanspub.43983-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Moerloose, P.D., Casini, A. and Neerman-Arbez, M. (2013) Congenital Fibrinogen Disorders: An Update. Seminars in Thrombosis and Hemostasis, 39, 585-595. &lt;br&gt;https://doi.org/10.1055/s-0033-1349222</mixed-citation></ref><ref id="hanspub.43983-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Arai, S., Kamijo, T., Takezawa, Y., Sugano, M., Nakazawa, H., Yanagisawa, R., Uehara, T., Honda, T. and Okumura, N. (2020) Acquired Dysfibrinogenemia: Monoclonal λ-Type IgA Binding to Fibrinogen Caused Lower Functional Plasma Fibrinogen Level and Abnormal Clot Formation. International Journal of Hematology, 112, 96-104.  
&lt;br&gt;https://doi.org/10.1007/s12185-020-02874-1</mixed-citation></ref><ref id="hanspub.43983-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Zitomersky, N.L., Menno, V. and Trenor, C.C. (2015) Thrombosis and Inflammatory Bowel Disease: A Call for Improved Awareness and Prevention. Inflammatory Bowel Diseases, 17, 458-470. &lt;br&gt;https://doi.org/10.1002/ibd.21334</mixed-citation></ref><ref id="hanspub.43983-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mori, T., Murata, M., Wakui, M., Muto, A. and Ikeda, Y. (2010) Acquired Dysfibrinogenemia Following Allogeneic Bone Marrow Transplantation. American Journal of Hematology, 56, 294-295.  
&lt;br&gt;https://doi.org/10.1002/(SICI)1096-8652(199712)56:4&lt;294::AID-AJH17&gt;3.0.CO;2-9</mixed-citation></ref><ref id="hanspub.43983-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">孙扬杰, 马林, 方斐, 孙瑞文. 多发性骨髓瘤高纤维蛋白原血症1例报告并文献复习[J]. 基层医学论坛, 2012, 16(11): 1489-1490.</mixed-citation></ref><ref id="hanspub.43983-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2020年修订) [J]. 中华内科杂志, 2020, 59(5): 341-346.</mixed-citation></ref><ref id="hanspub.43983-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chu, T.T., Wang, H., Lv, X., Qi, J.Q., Tang, Y.Q., Fan, Y., et al. (2021) Investigation of Fibrinogen in Early Bleeding of Patients with Newly Diagnosed Acute Promyelocytic Leukemia. Platelets, 32, 677-683.  
&lt;br&gt;https://doi.org/10.1080/09537104.2020.1799969</mixed-citation></ref></ref-list></back></article>